Metabolic & Cardiometabolic
ezetimibe decreases liver fat
Leans against Metabolic & Cardiometabolic 🔬 Includes disconfirming
Part of: 💊 ezetimibe
RefutedContestedStrong support
consensus score -0.22
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
3 support 3 contradict 0 tested null 1 mixed · 7 sources, 6 independent groups · 1 superseded — pooled inside a review, counted once
What the evidence shows
The human evidence is split, and this verdict sits close to the boundary with contested: of five human rows, two randomised trials found no reduction in liver fat, one randomised trial and one observational study found one, and a meta-analysis came out mixed. Everything measured is a surrogate — MRI fat fraction and liver enzymes, not fibrosis or any clinical outcome.
The evidence (8)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Esim O, Adatepe S, Aksoy OA, Goksel BA, Yilmaz T, Baykal B, Yucel Ç, Kablan SE, Eylem CC, Kocak E, Erdogan H, Ozkan CK, Nemutlu E, Savaser A, Ozkan Y 2025 · International journal of pharmaceutics | animal | supports | low | High-fat-diet NAFLD rat model treated with free ezetimibe vs RBC-membrane-coated or uncoated PLGA nanoparticle-encapsulated ezetimibe; all ezetimibe-treated groups (including free-drug) showed significant reductions in hepatic lipid accumul |
| Patel J, Bettencourt R, Cui J, Salotti J, Hooker J, Bhatt A, Hernandez C, Nguyen P, Aryafar H, Valasek M, Haufe W, Hooker C, Richards L, Sirlin CB, Loomba R 2016 · Therap Adv Gastroenterol | observational | supports | moderate | MRI-PDFF validation in NASH: quantifies hepatic-fat decline used as endpoint in ezetimibe trials |
| Cho Y, Rhee H, Kim YE, Lee M, Lee BW, Kang ES, Cha BS, Choi JY, Lee YH 2022 · BMC Med | RCT | supports | low | ESSENTIAL open-label per-protocol n=64 combo(eze+rosuva) MD 3.2%; ezetimibe added effect, no fibrosis; not blinded/placebo ↩ SUPERSEDED — pooled in the review above, counted once |
| Jiao B, Wang B, Liu B, Zhao J, Zhang Y 2024 · Front Endocrinol | meta-analysis | contradicts | low | Jiao 2024, 10 RCTs / 578 NAFLD-NASH patients, ezetimibe 10 mg/d; only 1 of 10 control arms was placebo. LIVER FAT IS NULL ON EVERY ENDPOINT THE PAPER MEASURED: MRI-PDFF k=2/n=109, MD -2.44 (95% CI -5.25, 0.37), P=0.09, I2=0%; histologic steatosis k=2/n=67, MD 0.00 (-0.16, 0.16), P=1.00; NAS k=3/n=107, P=0.37; ballooning P=0.68; LSM k=2/n=120, P=0.91; fibrosis k=2/n=75, P=0.69. Authors' own summary: 'no marked improvements were noted in levels of ALT, TG, HDL, FPG, HOMA-IR, steatosis, or fibrosis'. The positive results are OFF-OBJECT for a liver-FAT claim - AST k=9/n=549 SMD -0.40, GGT k=6 SMD -0.49, but ALT NULL k=10/n=574 SMD -0.22 P=0.15 - plus TC, LDL-C, hs-CRP, IL-6; HbA1c ROSE (k=3/n=141, SMD +0.40, P=0.02). Null on a directional claim = contradicts (CONVENTIONS 5). The prior extract's 'improved liver fat/aminotransferases (heterogeneous)' fails on all three counts: fat was null, ALT was null, and the deciding MRI-PDFF pool had I2=0%. Quality low: the paper reports 8/10 trials with no allocation-concealment detail and 'more than half' with bias concerns, pools nine different comparators (diet, statins, acarbose, polyene phosphatidylcholine), and applies Egger's at k=2-4 against its own stated >=10-study rule; its abstract omits every liver-fat null. INDEPENDENCE (flagged, not fixed): the MRI-PDFF pool IS ESSENTIAL (Cho 2022) + MOZART (Loomba 2015), both of which vote separately on this claim; names them correctly. |
| Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, Soaft L, Hooker J, Kono Y, Bhatt A, Hernandez L, Nguyen P, Noureddin M, Haufe W, Hooker C, Yin M, Ehman R, Lin GY, Valasek MA, Brenner DA, Richards L, San Diego Integrated NAFLD Research Consortium (SINC) 2015 · Hepatology | RCT | contradicts | high | MOZART randomised placebo-controlled trial, liver fat by MRI-PDFF across nine colocalised segments plus MR elastography: 'Ezetimibe was NOT significantly better than placebo at reducing liver fat' (between-arm mean difference -1.3%, p=0.4). Within-arm fat fell in the ezetimibe group (15%->11.6%, p<0.016) but not placebo (18.5%->16.4%, p=0.15) - a within-arm change without a between-arm difference is not an effect. Well-powered imaging null on a directional claim -> contradicts per CONVENTIONS 5. |
| Xue F, Ma W, Gao J, Chen J, Yue W, Bu P, Chen Q, Chen H, Sheng J, Chen L, Liu F, Li G, Zhu C, Zhong B, Zhang J, Cai Q, Wang L, Chen Y, Pei Z, Yao L, Lv L, Gao Y, Xia B, Ji X, Liu Y, Du L, Ma G, Hao K, Li F, Wu T, Huo Y, Wei L 2026 · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | RCT | contradicts | high | Phase 2a RCT, 210 Asian MASLD patients, 5 arms (HSK31679 3 doses, ezetimibe 10mg, placebo) for 12 weeks; primary endpoint relative change in MRI-PDFF liver fat content. Ezetimibe arm result not reported as significantly different from place |
| Xu Y, Zhang N, Wickramasinghe PB, Veera K, Parupalli P, Dao A, Liu J, Anand R, Langley LE, Eadha S, Iqbal H, Liu C, Bian F, Jia L 2026 · Biomolecules | animal | supports | moderate | Wild-type mice on NIAAA alcohol-feeding model +/- dietary cholesterol +/- ezetimibe (0.001% w/v); ezetimibe protected mice from cholesterol+alcohol-induced hepatic triglyceride accumulation and normalized liver cholesterol content, via enha |
| Masson W, Barbagelata L, Nogueira JP 2025 · J Lipid Atheroscler | meta-analysis | mixed | moderate | Masson2025 SR 18 studies/933: 5/8 ezetimibe RCTs no sig change; placebo-RCTs MOZART/LISTEN null; histo gains only non-RCT |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.